[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-therapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,42,69,93,118,143,168,196,219,242,269,293,318,343,367,391,419,442,462,496,518],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100528328","phase-3-18f-fluc-petmr-in-patients-with-brain-mets-100528328",false,"NCT06159335","18F-FLUC PET\u002FMR in Patients With Brain Mets","Use of 18F-Fluciclovine PET for Discerning Tumor From Treatment Change in Patients With Brain Metastases Undergoing Immunotherapy","Inclusion Criteria:\n\n* Age 18 years or older\n* Able and willing to provide informed consent\n* Has a brain metastasis diagnosis with at least one single visible contrast enhancing metastatic lesion on brain MRI\n* Received radiation therapy at some point in the last 2 years\n* Is currently being treated with or has been treated with any other concurrent systemic therapy (multi-modal therapy) in the past 6 months, which would include immunotherapy, targeted therapy, or systemic chemotherapy, immunotherapy, or chemotherapy following radiation therapy.\n* Patients are eligible for the study if their most recent standard-of-care MRI, used to assess disease location and extent, raises the question of tumor recurrence versus treatment-related changes. This concern can be noted by the radiologist or other members of the multidisciplinary care team, such as during a multidisciplinary conference. Additionally, if there are clinical concerns based on evolving exam findings or symptoms, and the treating physician suspects progression versus treatment-induced changes, the patient is also eligible for the study.\n* Be able to lie still for 30-60 minutes during the imaging procedure\n* Willing and able to undergo PET\u002FMRI or PET\u002FCT\n* Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:\n\n  * The subject has their own prescription for the medication\n  * The informed consent process is conducted prior to the self-administration of this medication\n  * They come to the research visit with a driver\n\nExclusion Criteria:\n\n* Subject unable or unwilling to provide informed consent\n* Subject is pregnant\n* Subject with contraindication(s) to or inability to undergo a PET\u002FMR or PET\u002FCT\n* Known allergy to 18F-Fluciclovine or any of its excipients","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The goal of this clinical trial is to use new imaging methods to help in finding out whether the imaging shows that there is a tumor in people with a brain metastasis. The main question it aims to answer is whether positron emission tomography (PET) and magnetic resonance imaging (MRI) find cancerous tissue better than other types of imagining.\n\nParticipants will undergo a single PET\u002FMRI scan, followed by a separate MRI scan with a tracer. Study participation will last about 3 hours.",[26,27,28],"Brain Metastasis","Radiation Therapy","Immunotherapy, Active","RECRUITING","2026-06-17",{"date":32,"type":33},"2026-06-22","ACTUAL",{"date":35,"type":33},"2024-01-10",{"date":37,"type":20},"2027-06",{"name":39,"class":40},"University of Wisconsin, Madison","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":41},"100641784","evaluation-of-the-benefits-of-sophrology-for-patients-undergoing-radiotherapy-100641784","NCT07652060","EVALUATION OF THE BENEFITS OF SOPHROLOGY FOR PATIENTS UNDERGOING RADIOTHERAPY","SORA-RT","Inclusion Criteria:\n\n* Adults with cancer requiring radiation therapy lasting at least 3 weeks,\n* Primary sites: ENT cancers, Thoracic cancers, Breast cancers, Pelvic cancers, Gastrointestinal cancers\n* WHO performance status 0 or 1\n\nExclusion Criteria:\n\n* Patients undergoing treatment other than radiation therapy alone\n* Patients already attending sophrology sessions elsewhere\n* Patients under protective measures\n* Patients receiving psychiatric care\n* Pregnant or breastfeeding patients\n* Patients not covered by social security",{"count":50,"type":20},54,[52],"NA","Anxiety is a common symptom among patients undergoing radiation therapy, stemming from their cancer diagnosis, anticipation of side effects, and the specific challenges associated with the treatment sessions. The technical nature of the treatment, the medical setting, and the daily repetition of sessions can exacerbate this anxiety. This anxiety is likely to impair quality of life, treatment tolerance, and patient adherence to the care pathway. In this context, managing anxiety during radiation therapy is a major challenge in supportive care. Since 2021, the Finistère Center for Radiation Therapy and Oncology has been offering sophrology sessions to its cancer patients as part of a comprehensive support program aimed at improving their quality of life. The aim of the study is to assess the potential benefits of this approach and better understand its impact on patients' experiences during treatment.",[27],[56,57,58],"radiation therapy","anxiety","sophrology","NOT_YET_RECRUITING","2026-06-11",{"date":62,"type":33},"2026-06-16",{"date":64,"type":20},"2026-07-01",{"date":66,"type":20},"2028-08-31",{"name":68,"class":40},"Clinique Pasteur Lanroze",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":41},"100617896","effectiveness-of-virtual-reality-vr-in-the-management-of-anxiety-for-patients-undergoing-radiotherapy-100617896","NCT07324577","Effectiveness of Virtual Reality (VR) in the Management of Anxiety for Patients Undergoing Radiotherapy","Effectiveness of Virtual Reality in the Management of Anxiety for Patients Undergoing Radiotherapy","RELAX","Patients:\n\nInclusion Criteria:\n\n* Participants planned for radiation therapy for 15 or more treatments with non-neutron generating energies (10 MV or less) per study PI for prostate, breast, lung, or head and neck cancer. Neutrons have the potential to damage the VR headset device and are generated for energies above 10 MV.\n* Age 18 years or older at the time of consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 at the time of enrollment.\n* Ability to understand and the willingness to sign an IRB-approved informed consent document directly.\n\nExclusion Criteria:\n\n* Previous radiation therapy\n* VR device is determined to impede the radiation dosage during the VR device simulation and treatment planning\n* Participants with primary brain tumors, brain metastases, and cancer involving the sinuses, orbits, nose, or ears, are excluded from this clinical trial because the VR device may obstruct the area being treated\n* Participants with uncontrolled inter-current illness including but not limited to psychiatric illness\u002Fsocial situations that would limit compliance with study requirements per treating radiation oncologist.\n* Participants with known epilepsy, significant motion sickness, severe uncorrected visual impairment, severe uncorrected hearing impairment, or seizures, per participant report.\n* Participants with skin defects, infections, or open wounds in the area where the VR device is applied (face or scalp) or in the eyes per treating radiation oncologist.\n* Participants with pacemakers, internal defibrillators, hearing aid, or other implanted medical device. The Meta Quest device contains magnets and components that emit magnetic\u002Felectromagnetic fields which could affect the operation of nearby electronics and medical devices.\n\nRadiation Therapists:\n\nInclusion Criteria:\n\n* Agreement to participate after reviewing the information sheet\n* Radiation therapist at AHWFBCCC High Point who has treated at least one participant who enrolled on to the study and used the VR device.",{"count":50,"type":20},[52],"The purpose of this study is to evaluate the use and functionality of virtual reality (VR) during radiation therapy treatments for patients with prostate, breast, lung, or head and neck cancer.",[27,81],"Virtual Reality",[81,83,27],"Cancer","2026-05-21",{"date":86,"type":33},"2026-05-22",{"date":88,"type":33},"2026-05-07",{"date":90,"type":20},"2029-02-01",{"name":92,"class":40},"Wake Forest University Health Sciences",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":41},"100634482","caix-pet-ct-guided-radiation-therapy-in-ccrcc-100634482","NCT07540260","CAIX PET\u002F CT Guided Radiation Therapy in CcRCC.","COSTAR-002","Inclusion Criteria:\n\nAdults (≥18 years) Histologically confirmed clear cell renal cell carcinoma Recurrent or metastatic disease Planned or ongoing first-line systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) Dual PET\u002FCT imaging available (FDG PET\u002FCT and CAIX-targeted PET\u002FCT) and eligible for radiotherapy planning Multidisciplinary assessment confirms radiotherapy is feasible to treat ≥75% of detectable lesions Able to provide written informed consent\n\nExclusion Criteria:\n\nUnable to receive stereotactic radiotherapy as planned Uncontrolled serious comorbidities or active infection Pregnant or breastfeeding Unable or unwilling to comply with study procedures and follow-up",{"count":101,"type":20},70,[52],"This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and undergo dual PET\u002FCT imaging (FDG PET\u002FCT and a CAIX-targeted PET\u002FCT) to map disease sites. When feasible, PET\u002FCT-visible lesions will be treated with image-guided stereotactic ablative radiotherapy (SABR). Patients will be followed to evaluate progression-free survival, local control of treated lesions, and treatment-related adverse events (planned enrollment: \\~70).",[27,105,106],"Metastatic Renal Cancer","Recurrent Renal Cell Cancer",[108,105,106],"SBRT","2026-04-13",{"date":111,"type":33},"2026-04-20",{"date":113,"type":33},"2025-11-01",{"date":115,"type":20},"2030-12-31",{"name":117,"class":40},"Peking University First Hospital",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":21,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":140,"locationsCount":142},"100573449","activity-coaching-during-pelvic-radiation-therapy-100573449","NCT06746428","Activity Coaching During Pelvic Radiation Therapy","ACTIVATE: A Pilot Randomized Activity Coaching Trial to Increase Vitality and Energy During Post-operative Pelvic Radiation Therapy for Endometrial Cancer","ACTIVATE","Inclusion Criteria:\n\n* At least 18 years of age\n* Pathologic diagnosis of endometrial cancer (any histology, Stage I-IVA)\n* Has undergone modified radical or radical hysterectomy\n* Plan to receive adjuvant treatment with pelvic external beam radiation therapy at ISCI\n* ECOG performance status of 0-1\n* Patient has a computer, smart phone, or tablet virtual access to the web-based platform and email\n* Able to read, understand and provide written informed consent\n* Deemed appropriate for unmonitored exercise by treating physician based on the following evidence-based criteria (1)\n\n  * Walk without any assistance or assistance device\n  * Absence of significant cognitive impairment\n  * Absence of high risk for falls\n* Participant does not need to refrain from any activity\n\nExclusion Criteria:\n\n* Unable to schedule and attend coaching visits\n* Participation in a regular exercise program of ≥150 minutes of moderate intensity exercise a week at baseline\n* Unable to perform the five-times stand test\n* Medical comorbidities including:\n\n  * Unstable angina\n  * Uncontrolled dysrhythmias\n  * Acute pulmonary embolus\n  * Active pulmonary infection","FEMALE",{"count":128,"type":20},16,[52],"Research has shown that for women who are undergoing pelvic radiation therapy, fatigue is a common side effect. Fatigue that occurs during radiation therapy can make it harder to perform daily living activities. While there are studies that recommend exercise as a treatment for fatigue in cancer patients and survivors, there are currently no studies that focus on the role of exercise for women undergoing pelvic radiation therapy. The purpose of this study is to see if incorporating an activity coaching program is helpful in improving treatment-related fatigue for women undergoing pelvic radiation therapy for endometrial cancer.",[27,132,133],"Gynecologic Cancer","Exercise Therapy","2026-03-02",{"date":136,"type":33},"2026-03-03",{"date":138,"type":33},"2025-01-27",{"date":64,"type":20},{"name":141,"class":40},"Inova Health Care Services",4,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":150,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":154,"conditions":155,"keywords":156,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100241539","imaging-acquisition-and-analysis-methods-for-optimization-of-mri-radiation-oncology-simulation-and-response-assessment-100241539","NCT02422550","Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment","Development and Evaluation of Imaging Acquisition and Analysis Methods for Optimization of MRI and\u002For CT in Radiation Oncology Simulation, Treatment Planning, and Response Assessment","Inclusion Criteria:\n\n* Men and women age 18 or older\n\nExclusion Criteria:\n\n* Anyone who would be normally excluded from undergoing an MRI examination as per Memorial Hospital for Cancer and Allied Diseases Screening Questionnaire\n* Participants\u002Fvolunteers with a pacemaker, aneurysm clip or any other condition that would warrant avoidance of a strong magnetic field\n* Female participants\u002Fvolunteers who are pregnant or nursing\n* Participants\u002FVolunteers who are unable to comply or complete the MRI exam due to claustrophobia or high levels of anxiety\n* Participants\u002FVolunteers from the vulnerable population, as defined by 45 CFR 46.\n* Participants at higher risk due to age, frailty, or the emergent nature of their condition.",true,{"count":152,"type":20},837,"OBSERVATIONAL","Magnetic resonance imaging (MRI) is currently one of the standard diagnostic imaging methods used to diagnose tumor stage before treatment in the Radiation Oncology Department. It is also used to check responses to radiation after treatment. However, MRI isn't traditionally used in planning for radiation treatment or in checking treated tumor and tissue changes during radiation treatment. The goal is to find out the possible benefits of MRI imaging techniques in these settings of radiation treatment. The research aims are to study the possibility of using devices with new abilities such as the MR-Linac. The MR-Linac combines a radiation treatment machine with a diagnostic MRI scanner. This device will improve the quality of MRI-guided radiation treatment. The MR-Linac has functions that are currently not available in other combined imaging and radiation delivery devices. The MR-Linac does not provide additional imaging capabilities that are not currently available in other imaging devices.\n\nParticipating in this study would NOT change the current treatment plans, this will allow the investigators to use the MRI methods in research and future patient care.",[27],[157,158,159],"MRI","15-073","participants undergoing radiation therapy",{"date":136,"type":33},{"date":162,"type":33},"2015-04-09",{"date":164,"type":20},"2027-04",{"name":166,"class":40},"Memorial Sloan Kettering Cancer Center",7,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":175,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":21,"phases":178,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":167},"100437962","metastasis-directed-stereotactic-body-radiotherapy-for-oligo-metastatic-hormone-sensitive-prostate-cancer-100437962","NCT04983095","Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer","METRO","Inclusion Criteria:\n\n1. Histologically confirmed prostate cancer (ICD-O-3 C61)\n2. WHO\u002FECOG performance status 0-1\n3. 1-3 skeletal or extra pelvic lymph node metastases detected by PSMA-PET\u002FCT in de novo prostate cancer or PSA-relapse after definitive RT or prostatectomy\n4. Willing and able to provide informed consent-\n\nExclusion Criteria:\n\n1. Castration resistant prostate cancer (progression with castrate levels of testosterone)\n2. Any treatment known to affect PSA (including ADT) for prostate cancer within 6 months (exception: ADT started due to oligometastatic disease within 2 weeks of study entry)\n3. Patient eligible for other treatment (e.g., early docetaxel) than standard treatment described in the protocol as judged by treating physician\n4. Life expectancy \\\u003C3 years by any reason, including concomitant or previous malignancies\n5. Previous radiotherapy or surgery that may interfere with the planned treatment (including intra-prostatic recurrence if previous RT to the prostate)\n6. \\> 3 PSMA-PET\u002FCT positive target lesions (excluding the prostate and regional lymph node metastasis in de novo patients or prostate bed and or regional lymph node metastasis in recurrent patients)\n7. PSMA-PET verified metastases other than skeletal or lymph nodes\n8. Metastases in base of scull and\u002For calotte\n9. Any target lesions not treatable with image guided RT (IGRT) due to overlap with previous RT fields or exceeded dose constraint to OAR(s) as specified in study protocol","MALE",{"count":177,"type":20},118,[52],"The study is an open label, multi-centre, randomized phase III study. The patients will be randomised in a 1:1 ratio to treatment consisting of\n\n* Arm A: MD-SBRT in addition to standard treatment\n* Arm B: Standard treatment\n\nStudy population: Patients with hormone sensitive prostate cancer (HSPC) with oligometastatic disease detected by PSMA-PET\u002FDT. This includes patients with de novo oligometastatic HSPC and recurrent HSPC after primary RT or prostatectomy.\n\nPrimary endpoint: Failure free survival\n\nSecondary endpoints:\n\n* Predictive value of investigated biomarkers in blood and imaging\n* Acute and late toxicity after MD-SBRT\n* PROM at 3 months, 1, 3 and 5 years\n* Castration resistant prostate cancer, CRPC\n* Overall survival\n* Differences in outcome between patients by strata\n\nStratification: To avoid imbalance between treatment arms the minimisation method will be used to achieve balance between de novo oligo-metastatic and oligo-recurrent patients, as well as treatment site.\n\nSafety evaluation: Adverse events and side effects graded according to CTCAE v5.0 will be collected every 6th month. Serious Adverse Events are to be reported within 24 hours throughout the study duration.\n\nStatistical methods: Survival endpoints will be calculated using the Kaplan-Meier method with differences compared using the stratified log-rank test. Randomization time is set as baseline time. Pre-planned subgroup analysis will occur based on pre-specified stratification variables. A Cox multivariable regression model will be used to determine factors predictive of survival. Safety analysis will be performed with Mann-Whitney U-test or Fishers exact test.\n\nCriteria for evaluation: Per protocol (patients that have started study treatment) and Intention to treat (all included patients).\n\nPlanned sample size: 118 patients\n\nAnalysis plan:\n\nThe primary end point will be analysed after pre-specified number of events have occurred. All patients randomised to SBRT will be followed minimum 60 months for toxicity. Safety analysis of acute toxicity will take place after median follow up of 6 months. Safety analysis of late toxicity will be analysed after study closure.\n\nDuration of the study:\n\nThree to five years inclusion. 72 months of follow-up after randomization of the last patient.",[181,27,182],"Prostate Cancer Metastatic","Positron-Emission Tomography",[184,185,186],"Oligometastatic Prostate Cancer","Hormone Sensitive","Stereotactic Body Radiotherapy","2026-02-11",{"date":189,"type":33},"2026-02-17",{"date":191,"type":33},"2021-10-27",{"date":193,"type":20},"2033-12",{"name":195,"class":40},"Karin Soderkvist",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":21,"phases":205,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":216,"locationsCount":218},"100624903","phase-2-gccc-2578-randomized-photon-vs-proton-rt-for-newly-diagnosed-gynecologic-primaries-100624903","NCT07415681","GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries","A Phase II, Randomized, Open-Label, Single-Center Study Comparing Intensity Modulated Proton Therapy Versus Volume Modulated Arc Therapy in Patients Receiving Pelvic Nodal Irradiation for Newly Diagnosed Gynecologic Primaries","Inclusion Criteria:\n\n1. a. Newly diagnosed endometrial cancer after TAH\u002FBSO and nodal sampling, sentinel LN biopsy or pelvic nodal dissection planning to receive sequential chemotherapy and radiation or concurrent chemoradiotherapy or b. cervical cancer planning to receive definitive chemoradiation with HDR brachytherapy boost\n2. Histologic confirmation of malignancy (primary only)\n3. ≥ 18 years of age\n4. ECOG performance status ≤ 2\n5. Patient must have the ability to understand and the willingness to sign a written informed consent document or when appropriate, have an acceptable surrogate capable of giving consent on the subject's behalf.\n6. Insurance approval for IMPT\n\nExclusion Criteria:\n\n1. Metastatic disease beyond para-aortic lymph nodal region\n2. Residual tumor after surgery exceeding 2 cm in maximum dimension in patients with endometrial cancer.\n3. FIGO 2014 stage III-IVA cervix cancer planning to receive concurrent pembrolizumab.\n4. Cervical cancer with inability to receive concurrent chemotherapy.\n5. Any prior pelvic radiation.\n6. Treatment with other investigational agents.\n7. Carcinosarcoma.\n8. Creatine clearance \\\u003C30 mL\u002Fm2\n9. Unable to lie flat during or tolerate radiation.\n10. Refusal to sign informed consent.\n11. Any additional active cancer that would interfere with the primary study endpoints",{"count":204,"type":20},116,[206],"PHASE2","The purpose of study is to compare the side effects of two different forms of radiation for endometrial and cervical cancer. If you decide to enroll in this study, you will be randomized to one of two treatment groups. This study will compare two standard of care treatments: \"Conventional\" pHoton radiation versus pRoton radiation.",[209,210,27],"Gynaecologic Cancer","Cervical Cancer","2026-02-09",{"date":189,"type":33},{"date":214,"type":20},"2026-03",{"date":193,"type":20},{"name":217,"class":40},"University of Maryland, Baltimore",5,{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":175,"minAge":17,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":241},"100560893","sabr-combined-with-targeted-therapy-and-anti-pd-1-for-recurrent-or-metastatic-renal-cancer-100560893","NCT06583070","SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer","Cohort Study of SABR Combined With Targeted Therapy and Anti-PD-1 Versus Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cell Carcinoma Patients","COSTAR","Inclusion Criteria:\n\n* Patients with histologically confirmed renal cancer; diagnosed with recurrent or metastatic renal cancer via PET\u002FCT or other whole-body imaging.\n* Evaluated by the radiation oncology and imaging departments as having at least one lesion amenable to radiation therapy.\n* Planning to undergo or currently receiving first-line or second-line targeted therapy combined with immunotherapy.\n* Voluntarily agrees to participate in the study and signs an informed consent form.\n* Male or female, aged ≥18 years (inclusive).\n* Expected survival of ≥12 weeks.\n* At least one measurable lesion as per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.\n* European Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate cardiac, bone marrow, liver, and renal function.\n* Willing and able to comply with the study procedures and follow-up schedule.\n\nExclusion Criteria:\n\n* Extensive, multiple metastases;\n* Presence of central nervous system metastases and\u002For carcinomatous meningitis.\n* Toxicity from previous treatments not yet recovered to grade 0-1 (excluding grade 2 alopecia);\n* Other severe, uncontrollable co-morbid conditions that could affect protocol compliance or confound interpretation of results, including active opportunistic or severe progressive infections, uncontrolled diabetes, uncontrolled hypertension, cardiovascular diseases (defined as New York Heart Association Class III or IV heart failure, second-degree or higher heart block, myocardial infarction within the last 12 months, unstable arrhythmias or angina, stroke within the last 6 months), or pulmonary diseases (interstitial pneumonia, obstructive pulmonary disease, and symptomatic bronchospasm history), deep vein thrombosis or pulmonary embolism within the last 6 months;\n* Diagnosed with other malignancies within 5 years prior to enrollment, except:\n* Localized low-risk prostate cancer (defined as stage ≤T2b, Gleason score ≤7, and PSA ≤20ng\u002FmL at diagnosis, who have undergone curative treatment with no recurrence of prostate-specific antigen);\n* Malignancies treated with a curative intent that are considered cured, including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated with surgery;\n* Pregnant or breastfeeding women;\n* Positive HIV test result;\n* Active hepatitis B or C infection;\n* Active tuberculosis;\n* Any other conditions, metabolic abnormalities, physical examination or laboratory findings that in the investigator's judgment might indicate an unsuitability for the study drug, could interfere with the interpretation of study results, or place the patient at high risk if they participate in the study;\n* Estimated insufficient compliance with the clinical study.","85 Years",{"count":229,"type":20},300,"Renal cancer ranks seventh in incidence among men and sixth among women in the Beijing area, with Peking University First Hospital treating over 1,000 kidney cancer patients annually. Once recurrence or metastasis occurs, the prognosis is poor, with median progression times of 1-2 years after first-line systemic therapy (targeted therapy combined with immunotherapy). Enhancing local control of lesions is key to improving overall survival. Combining local radiotherapy with systemic treatment may be one approach to address this issue. Currently, Stereotactic Ablative Radiotherapy (SABR) enables precise tumor ablation and can activate the body's immune response. Studies show that the one-year local control rate after SABR exceeds 90%. Preliminary research by the applicant has shown that the combination of drug therapy and SABR for recurrent metastatic renal cancer can extend progression-free survival beyond two years, with earlier intervention leading to more significant survival improvements. This study aims to evaluate the efficacy and safety of combining SABR with targeted and immunotherapy for recurrent metastatic renal cancer through a multicenter, bidirectional cohort design, exploring new therapeutic strategies.",[27,105,106],[108,105,106],"2026-01-27",{"date":235,"type":33},"2026-01-28",{"date":237,"type":33},"2024-02-02",{"date":239,"type":20},"2027-03-31",{"name":117,"class":40},2,{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":248,"eligibilityCriteria":249,"healthyVolunteers":150,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":250,"targetDuration":4,"studyType":21,"phases":252,"briefSummary":253,"conditions":254,"keywords":259,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":268},"100558090","locally-optimised-contouring-with-ai-technology-for-radiotherapy-100558090","NCT06546592","Locally Optimised Contouring With AI Technology for Radiotherapy","LOCATOR - Locally Optimised Contouring With AI Technology for Radiotherapy","LOCATOR","Inclusion Criteria:\n\n* 18 years and older who are planned for primary breast malignancy\n* ECOG performance 0-2\n* Ability to understand and willingness to sign a written informed consent document\n* The target volume must be able to be objectively reviewed by current published national or international clinical guidelines\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Patients unable to understand consent documents",{"count":251,"type":20},444,[52],"LOCATOR is a multicentre phase II randomised clinical trial that is looking at the process of contouring in radiation treatment for breast cancer patients. This study looks at whether contouring aided by artificial intelligence (AI) is comparable in quality to that of contouring done completely manually by a radiation oncologist. We are also looking at whether AI assisted contouring saves radiation oncologists time when compared to fully manual contouring.\n\nLOCATOR uses the LOCATOR software which is an in-house software developed locally and trained on local data.",[255,256,27,257,258],"Contouring","Segmentation","Artificial Intelligence","Deep Learning",[255,256,27,257,258],{"date":261,"type":33},"2026-01-29",{"date":263,"type":33},"2025-02-11",{"date":265,"type":20},"2030-04-30",{"name":267,"class":40},"Royal North Shore Hospital",3,{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":21,"phases":278,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":41},"100560599","early-phase-1-intraoral-hypothermia-device-for-preserving-taste-during-radiation-100560599","NCT06579248","Intraoral Hypothermia Device for Preserving Taste During Radiation","Study of a Novel Intraoral Hypothermia Device for Preserving Taste During Radiation Therapy for Squamous Cell Carcinoma of the Larynx","Inclusion Criteria:\n\n* Patients being treated with combination radiation therapy and chemotherapy (definitive) for locally advanced (AJCC 8th cT3-4 or cN+) squamous cell carcinoma of the larynx.\n* Age ≥ 18.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Patients will engage in the informed consent process and provide study-specific informed consent prior to study entry and must be able to fill out toxicity and quality of life related questionnaires.\n* Patients should be concurrently treated with any of the following chemotherapy drugs: cisplatin, carboplatin, and cetuximab.\n\nExclusion Criteria:\n\n* Patients receiving other forms of therapy intended to reduce taste dysfunction.\n* Patients with metastatic disease.\n* Patient with allergies or hypersensitivity to materials in the intraoral bolus.\n* Patients who have received prior chemotherapy or radiation therapy for head and neck cancer.\n* Patients who decline to use or cannot tolerate the intraoral device.\n* Patients who are current or recent (within 3 months of treatment initiation) cigarette smokers.\n* Patients who are unable to complete the required forms; however, verbal completion is adequate if recorded on the form daily.\n* Patients with uncontrolled serious illness including, but not limited to, ongoing or serious active infection requiring IV antibiotics for over 30 days, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia other than chronic, stable atrial fibrillation, immunocompromised state, significant hepatic insufficiency, significant hematological disease, and any serious or unstable psychological condition.\n* Patients who are on any of the following medication that cannot find a suitable substitute during the study period: acetazolamide, maribavir (TAK-620, Phase 3 trial drug), eszopiclone, topiramate, captopril, lithium, procainamide, terbinafine, and amiodarone.\n* Patients who have taste loss at baseline, assessed subjectively and objectively at the first encounter, will be excluded from the study and all analysis. They will be replaced with a new patient.\n* Patients who have tested positive for COVID-19 during the study period.",{"count":277,"type":20},15,[279],"EARLY_PHASE1","Radiation therapy to the head and neck region is known to cause taste dysfunction. Preliminary studies showed that cooling normal structures may lower damage caused by radiation. The purpose of this research study is to see if it is feasible to use an intraoral cooling device during radiation treatments to preserve or lower the decline of taste function.",[282,283,27],"Head and Neck Cancer","Taste Dysfunction","2026-01-13",{"date":286,"type":33},"2026-01-14",{"date":288,"type":33},"2024-11-12",{"date":290,"type":20},"2026-08-30",{"name":292,"class":40},"Henry Ford Health System",{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":300,"enrollmentInfo":301,"targetDuration":4,"studyType":21,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":41},"100614398","phase-2-node-sparing-low-dose-radiotherapy-concurrent-with-chemotherapy-and-pd-1-inhibitor-in-pmmrmss-high-risk-locally-advanced-colon-cancer-a-prospective-single-arm-phase-ii-trial-100614398","NCT07279077","Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR\u002FMSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial","MODIFI-L","Inclusion Criteria:\n\n1. Voluntarily signed written informed consent.\n2. Age ≥ 18 years and ≤ 75 years at the time of enrollment.\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n4. Life expectancy \\> 2 years.\n5. Histologically confirmed adenocarcinoma of the colon (without squamous or sarcomatoid components).\n6. Tumor biopsy immunohistochemistry (IHC) indicates pMMR (proficient Mismatch Repair), defined as positive expression of all four proteins: MSH1, MSH2, MSH6, and PMS2; or genetic testing indicates MSS (Microsatellite Stable).\n7. Staged as T4 and\u002For N+ (Stage IIB-III) according to the AJCC 8th edition, as evaluated by imaging (contrast-enhanced CT or MRI).\n8. Prior to enrollment, the subject must be evaluated by a surgeon responsible for the operation based on medical history to confirm eligibility for R0 resection with curative intent.\n9. No prior systemic or local anti-tumor therapy for colon cancer before study treatment, including radiotherapy, chemotherapy, immunotherapy, biologics, small molecule targeted therapy, etc.\n10. Subjects agree to the collection of tumor tissue and peripheral blood samples required during the screening period and the study process for use in related research.\n11. Adequate organ function:\n\n    a) Hematology (no use of blood components or cell growth factors within 7 days prior to the start of study treatment): i. Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹\u002FL (1,500\u002Fmm³). ii. Platelet count ≥ 100 × 10⁹\u002FL (100,000\u002Fmm³). iii. Hemoglobin ≥ 90 g\u002FL. b) Renal: i. Calculated Creatinine Clearance (CrCl) ≥ 50 mL\u002Fmin (calculated using the Cockcroft-Gault formula: CrCl (mL\u002Fmin) = {(140 - Age) × Weight (kg) × 0.85 \\[if female\\]} \u002F (Serum Creatinine (mg\u002FdL) × 72)).\n\n    ii. Urine protein \\\u003C 2+ or 24-hour urine protein quantification \\\u003C 1.0 g. c) Hepatic: i. Serum Total Bilirubin (TBil) ≤ 1.5 × ULN (Upper Limit of Normal). ii. AST and ALT ≤ 2.5 × ULN. iii. Serum Albumin (ALB) ≥ 28 g\u002FL. d) Coagulation: i. International Normalized Ratio (INR) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN.\n\n    e) Cardiac Function: i. Left Ventricular Ejection Fraction (LVEF) ≥ 50%.\n12. Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 3 days prior to study treatment (if the urine test result cannot confirm negativity, a serum pregnancy test is required, and the serum result prevails). If a female subject of childbearing potential engages in sexual activity with a non-sterilized male partner, she must use an acceptable method of contraception starting from screening and agree to continue using it for 120 days after the last dose of the study drug; cessation of contraception after this point should be discussed with the investigator. Periodic abstinence and rhythm methods are not acceptable forms of contraception.\n\n    1. Women of childbearing potential are defined as women who have not undergone surgical sterilization (i.e., bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or are not postmenopausal (menopause is defined as at least 12 consecutive months of amenorrhea without an alternative medical cause, with serum Follicle-Stimulating Hormone \\[FSH\\] levels within the laboratory reference range for postmenopausal women).\n    2. Highly effective contraception refers to methods with a low failure rate (e.g., less than 1% per year) when used consistently and correctly. Not all contraceptive methods are highly effective. In addition to barrier methods, female subjects of childbearing potential must independently use a hormonal contraceptive method (e.g., birth control pills) to ensure pregnancy does not occur.\n13. Subjects are willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study requirements.\n\nExclusion Criteria:\n\n1. Presence of suspicious metastatic lesions or locally advanced unresectable disease, regardless of disease stage.\n2. Subjects who have had other malignancies within 5 years prior to enrollment, excluding colorectal cancer. This excludes subjects with other malignancies cured by local therapy, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the breast.\n3. Receipt of any investigational drug or investigational device therapy within 4 weeks prior to the first dose of the study drug.\n4. Presence of intestinal obstruction, bowel perforation, or intestinal bleeding requiring emergency surgical intervention.\n5. Multiple primary colorectal cancers.\n6. History of pelvic or abdominal radiotherapy.\n7. Inability to swallow pills, malabsorption syndrome, or any condition affecting gastrointestinal absorption.\n8. Prior receipt of any systemic or local anti-tumor therapy for locally advanced colon cancer, including radical surgery, chemotherapy, radiotherapy, immunotherapy (including immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, or any therapy targeting tumor immune mechanisms), biologics, small molecule targeted therapy, etc.\n9. Receipt of non-specific immunomodulatory therapy (e.g., interleukins, interferons, thymosin, tumor necrosis factor, etc., excluding IL-11 used for thrombocytopenia) within 2 weeks prior to study treatment; receipt of traditional Chinese medicine or herbal preparations with anti-tumor indications within 1 week prior to study treatment.\n10. Active autoimmune disease requiring systemic treatment (e.g., disease-modifying antirheumatic drugs, corticosteroids, immunosuppressants) within the past two years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency) is not considered systemic treatment.\n11. History of non-infectious pneumonitis or pneumonia requiring systemic glucocorticoid treatment, or current history of interstitial lung disease.\n12. History of severe bleeding tendency or coagulation disorders; patients requiring prior or current long-term anticoagulation therapy (e.g., atrial fibrillation patients meeting CHADS2 score ≥ 2).\n13. Current uncontrolled comorbidities, including but not limited to decompensated liver cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, or psychiatric\u002Fsocial conditions that would limit the subject's compliance with study requirements or affect their ability to provide written informed consent.\n14. History of myocarditis, cardiomyopathy, or malignant arrhythmia.\n\n    1. Within 12 months prior to study treatment: unstable angina requiring hospitalization, congestive heart failure, or vascular disease (e.g., aortic aneurysm requiring surgical repair or peripheral venous thrombosis), or other cardiac damage that may affect the safety evaluation of the study drug (e.g., poorly controlled arrhythmia, myocardial infarction, or ischemia).\n    2. Within 6 months prior to study treatment: history of esophageal\u002Fgastric varices, severe ulcer, unhealed wound, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding.\n    3. Within 6 months prior to study treatment: any arterial thromboembolic event, NCI CTCAE v5.0 Grade 3 or higher venous thromboembolism, transient ischemic attack (TIA), cerebrovascular accident (stroke), hypertensive crisis, or hypertensive encephalopathy.\n    4. Within 1 month prior to study treatment: acute exacerbation of chronic obstructive pulmonary disease (COPD).\n    5. Current hypertension with systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg despite oral antihypertensive medication.\n15. Active or documented history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea).\n16. Severe infection within 4 weeks prior to study treatment, including but not limited to comorbidities requiring hospitalization, sepsis, or severe pneumonia; active infection requiring systemic anti-infective treatment within 10 days prior to study treatment (excluding antiviral treatment for Hepatitis B or C).\n17. Major surgery or severe trauma within 30 days prior to study treatment; minor local surgery within 3 days prior to study treatment (excluding Peripherally Inserted Central Catheter \\[PICC\\] or Central Venous Catheter \\[CVC\\] placement).\n18. History of immunodeficiency; positive HIV antibody test; currently receiving long-term systemic corticosteroids or other immunosuppressants.\n19. Known active tuberculosis (TB); subjects suspected of having active TB must undergo clinical examination to exclude it (e.g., sputum smear, chest X-ray); known active syphilis infection.\n20. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n21. Untreated active Hepatitis B subjects (HBsAg positive and HBV-DNA \\> 1000 copies\u002FmL \\[200 IU\u002FmL\\] or above the lower limit of detection); subjects with Hepatitis B are required to receive anti-HBV treatment during the study treatment period. Active Hepatitis C subjects (HCV antibody positive and HCV-RNA levels above the lower limit of detection).\n22. Receipt of live vaccines within 30 days prior to study treatment, or planned receipt of live vaccines during the study period.\n23. Known allergy to any component of the study drugs; known history of severe hypersensitivity reactions to other monoclonal antibodies.\n24. Known history of psychiatric illness, drug abuse, alcohol abuse, or substance abuse.\n25. Pregnant or lactating women.\n26. Prior or current presence of any disease, treatment, or laboratory abnormality that may confound study results, affect the subject's full participation in the study, or where participation is not in the subject's best interest.\n27. Local or systemic diseases not caused by malignancy; or diseases\u002Fsymptoms secondary to the tumor that lead to high medical risk and\u002For uncertainty in survival evaluation, such as tumor-related leukemoid reaction (WBC \\> 20 × 10⁹\u002FL), manifestations of cachexia (e.g., known weight loss of \\> 10% in the 3 months prior to screening), BMI ≤ 18 (BMI = Weight \\[kg\\] \u002F Height \\[m²\\]), etc.","75 Years",{"count":302,"type":20},38,[206],"Most colorectal cancers belong to the microsatellite stable (MSS) or proficient mismatch repair (pMMR) subtypes, with limited response to PD-1 inhibitors. Radiotherapy can increase the release of tumor-associated antigens, thereby improve responsiveness to PD-1 blockade in MSS\u002FpMMR rectal cancer. Tumor-draining lymph nodes are important sites for PD-1 inhibitors to exert antitumor effects, and studies have reported that direct radiation-induced damage and fibrosis can inhibit lymph node drainage and anti-tumor function. Accumulating evidence indicates that low-dose radiotherapy reprograms the tumor microenvironment (TME), transforming immunosuppressive 'cold' tumors into immunostimulatory 'hot' tumors. This transition is mediated by modulating the gut microbiota, eliciting innate and adaptive immune responses, inhibiting immunosuppressive cells, and promoting the infiltration of T and B lymphocytes.Therefore, this study aims to evaluate whether node-sparing low-dose radiotherapy (1Gy\u002F8f) concurrent with chemotherapy and PD-1 inhibitor can improve the pathological complete response (pCR) rate, enhance tolerability, and improve prognosis in patients with pMMR\u002FMSS high-risk locally advanced colon cancer.",[306,307,308,27],"Colon Cancer","Neoadjuvant Therapies","Immune Checkpoint Therapy","2025-12-24",{"date":311,"type":33},"2025-12-26",{"date":313,"type":33},"2025-11-26",{"date":315,"type":20},"2031-12-30",{"name":317,"class":40},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":16,"minAge":326,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":21,"phases":328,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":41},"100593395","phase-2-hormonal-receptor-hr-positive-her2-negative-breast-cancer-patients-treated-with-preoperative-elacestrant-and-pulsar-radiotherapy-100593395","NCT07005882","Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy","Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Adaptive Radiotherapy: a Phase II Study (HELP Trial)","HELP","Inclusion Criteria:\n\n1. Histologically proven HR-positive, HER2-negative BC\n2. Clinical disease stage II-III\n3. Post-menopausal female patients or male patients\n4. Eligible for neoadjuvant treatment and subsequent surgery\n5. No contraindication to MRI\n6. Patient able to understand and follow instructions during the trial\n7. Patient able and willing to give written informed consent, signed and dated\n8. Patient aged at least 50 years old\n9. Patient with tumor accessible for biopsy and surgery\n10. Patient with adequate bone marrow function at Screening, confirmed at Baseline, including:\n\n    1. ANC ≥ 1.5 × 109\u002FL; patients with documented benign cyclical neutropenia are eligible if white blood cell count is ≥ 1.5 × 109\u002FL, with ANC ≥ 1.0 × 109\u002FL, leukocytes ≥ 4.0 × 109\u002FL, and lymphocytes ≥ 0.6 × 109\u002FL;\n    2. platelets ≥ 100 × 109\u002FL;\n    3. hemoglobin ≥ 9 g\u002FdL (may have been transfused);\n11. International Normalized Ratio (INR) \\\u003C 1.5×Upper Limit of Normal (ULN); patients treated with vitamin K antagonist are eligible if INR \\\u003C 3\n12. Patient with adequate hepatic function at Screening, confirmed at Baseline, defined by:\n\n    a. total bilirubin level ≤1.5×ULN; patients with documented Gilbert disease are allowed if total bilirubin ≤3×ULN; aspartate aminotransferase (AST) level ≤2.5×ULN, and alanine aminotransferase (ALT) level ≤2.5×ULN,\n13. Patient with adequate renal function at Screening, confirmed at Baseline, defined by eGFR ≥ 30 mL\u002Fmin using 2021 CKD-EPI creatinine equation\n14. Patient with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n15. Life expectancy of at least 12 months according to the Investigator's judgement\n\nExclusion Criteria:\n\n* 1\\. Patients with stage IV disease 2. Patients with a history of any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, based on the Investigator's judgement, provides a reasonable suspicion of a disease or condition that contraindicates the use of RT and\u002For Elacestrant or that might affect the interpretation of the trial results or render the patient at high risk for treatment complications.\n\n  3\\. Patients with any significant co-morbidity which, according to the Investigator's judgement, makes patient compliance to trial conditions unlikely.\n\n  4\\. Patients with previous malignant disease (other than the tumor disease for this trial) within the last five (5) years (except adequately treated non-melanoma skin cancers and carcinoma in situ of skin, bladder, cervix, colon\u002Frectum, breast, or prostate) unless a complete remission without further recurrence was achieved at least two (2) years prior to Screening, and the patient is deemed to have been cured with no additional therapy required or anticipated to be required.\n\n  5\\. Patients with a history of uncontrolled intercurrent illness. 6. Patients with a known prior hypersensitivity or contraindications to Elacestrant or any component in its formulations.\n\n  7\\. Patients with severe acute or chronic medical conditions, including:\n  1. Immune colitis\n  2. Inflammatory bowel disease\n  3. History of severe vomiting or diarrhea not having resolved to Grade 1 at Baseline\n  4. Immune pneumonitis\n  5. Pulmonary fibrosis\n  6. Psychiatric conditions including recent (within the last year) or active suicidal ideation or behavior\n  7. Laboratory abnormalities that may increase the risk associated with trial participation or trial treatment administration or may interfere with the interpretation of trial results and, in the judgement of the Investigator, would make the patient inappropriate for entry into this trial.\n\n     8\\. Patients with a history of small intestine resection surgery or other major gastrointestinal surgery.\n\n     9\\. Patients with an active infection requiring systemic therapy with antibiotics (at both Screening and Baseline).\n\n     10\\. Patients with a known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome or multi-drug-resistant gram-negative bacteria.\n\n     11\\. Patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at Screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody Screening test positive).\n\n     12\\. Patients with increased anesthesiological risk (e.g. known or predicted difficult airway) if general anesthetic is required.\n\n     13\\. Premenopausal patients (defined as any woman who is not surgically sterile with a hysterectomy and\u002For bilateral oophorectomy or \\>12 months of amenorrhea and at least 50 years of age) 14. Patients aged less than 50 years old. 15. Patients with a known history of drug\u002Fsubstance abuse. 16. Patients participating in any other clinical trial within 30 days before Screening.\n\n     17\\. Patients receiving any other treatment that, in the opinion of the Investigator, might interfere with the trial.\n\n     18\\. Concomitant use of strong or moderate CYP3A4 inhibitors should be avoided and an alternative concomitant medicinal product with no or minimal potential to inhibit CYP3A4 should be considered.\n\n     19\\. Concomitant use of strong or moderate CYP3A4 inducers should be avoided and an alternative concomitant medicinal product with no or minimal potential to induce CYP3A4 should be considered.\n\n     20\\. Patients with a current drug or substance abuse. 21. Patients receiving chronic concurrent therapy within two (2) weeks before the trial treatment or expected therapy during the trial treatment period with:\n\n  \u003C!-- -->\n\n  1. Corticosteroids (except systemic corticosteroids up to 10 mg prednisolone or equivalent daily dose).\n  2. Immunosuppressive agents.\n  3. Antibiotics.\n  4. Any other anticancer therapy or concurrent anticancer treatment. 22. Patients who are unable to understand the protocol requirements, instructions and trial-related restrictions, the nature, scope, and possible consequences of the trial.\n\n     23\\. Patients who are unlikely to comply with the Protocol requirements, instructions and trial-related restrictions, e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the trial.\n\n     24\\. Patients with legal incapacity or limited legal capacity. 25. Patients with any condition which results in an undue risk for the patient during the trial participation according to the Investigator.","50 Years",{"count":5,"type":20},[206],"This is a proof-of-concept phase II trial to assess the safety (as primary endpoint) and clinical efficacy of neoadjuvant therapy with Elacestrant and PULSAR.\n\nThe study will enroll 21 postmenopausal patients with early HR+ HER2- node positive BC, clinically staged II-III. Patients will receive Elacestrant 345 mg orally once daily for 24 weeks and PULSAR on the MRI-based breast gross tumor volume (GTVt), consisting of 10 Gy \"pulse\" every 4 weeks for a maximum of 5 or less in case of radiologic complete response.\n\nSurgery will be planned 24 weeks after Elacestrant initiation and at least 2 weeks from the last pulse and will be performed as per recommended clinical practice. Patients will then receive adjuvant systemic therapy as per standard of care and postoperative RT to the locoregional lymph nodes in case of nodal residual disease, if indicated.",[331,332,333,27],"Breast Cancer Patients","Breast Cancer Early Stage Breast Cancer (Stage 1-3)","HR+\u002FHER2- Breast Cancer","2025-06-03",{"date":336,"type":33},"2025-06-05",{"date":338,"type":20},"2025-09-01",{"date":340,"type":20},"2028-03-01",{"name":342,"class":40},"Azienda Ospedaliero-Universitaria Careggi",{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":351,"targetDuration":4,"studyType":21,"phases":353,"briefSummary":354,"conditions":355,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":241},"100470454","stereotactic-multiple-fraction-radiotherapy-for-non-spine-bone-metastases-100470454","NCT05406063","Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases","Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases a Multicentre Prospective, Open Label, Randomised Controlled Phase 3 Non-inferiority Clinical Trial","SMILE","Inclusion Criteria:\n\n* Personally signed and dated written informed consent,\n* Histological diagnosis of malignancy,\n* Histologically or radiologically diagnosed bone metastasis,\n* Age ≥ 18 years\n* Pain or under pain control medication\n\nExclusion Criteria:\n\n* Pregnant or lactating women,\n* Women of childbearing potential or sexually active males not willing to use effective contraception while on treatment and 3 months after the end of treatment,\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.,\n* Prior radiotherapy to the intended treatment site,\n* Lesions \\> 5cm in maximum diameter,\n* Prior treatment with radioactive isotopes within 30 days of randomisation,\n* Spinal column, hands, feet, or head as intended treatment site,- Fracture at the intended treatment site,\n* Surgery required or previous surgery at the intended treatment site\n* Instability of the intended treatment site.",{"count":352,"type":20},162,[52],"To investigate, whether multi-fraction stereotactic body radiation therapy (SBRT) within 3 treatment fractions is non-inferior to the current standard of care of 5 fraction SBRT regarding pain response at 3 months after radiotherapy.",[27,356,357],"Bone Metastases","Pain","2025-05-19",{"date":360,"type":33},"2025-05-22",{"date":362,"type":33},"2022-06-01",{"date":364,"type":20},"2026-05-31",{"name":366,"class":40},"Kantonsspital Winterthur KSW",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":175,"minAge":17,"maxAge":227,"enrollmentInfo":375,"targetDuration":4,"studyType":21,"phases":377,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":241},"100582532","adjuvant-chemotherapy-for-high-malignant-prostate-cancer-100582532","NCT06864533","Adjuvant Chemotherapy for High Malignant Prostate Cancer","Evaluation of Chemotherapy With Adjuvant Docetaxel After Radiotherapy for Localized High Malignant Prostate Cancer: A Prospective Muti-center Non-Randomized Controlled Trial","PKUFH-GS5","Inclusion Criteria:\n\n1. Histologically confirmed prostate cancer diagnosed by biopsy or surgery with a Gleason score of 9-10 (GG grade 5) or containing Gleason 5 components.\n2. No evidence of distant metastasis confirmed by imaging.\n3. Expected to receive standard radical treatment or postoperative radiotherapy.\n4. Estimated survival time greater than 12 months.\n5. Aged ≥ 18 years.\n6. Karnofsky Performance Status (KPS) ≥ 80.\n7. Adequate blood count: white blood cell ≥ 3.5 × 10\\^9\u002FL, neutrophils ≥ 1.5 × 10\\^9\u002FL, platelets ≥ 100.0 × 10\\^\n\nExclusion Criteria:\n\n1. History of malignant tumors (except those cured for more than 5 years).\n2. Previous abdominal radiation therapy.\n3. Weight loss \\> 10% within the past 6 months.\n4. Pre-existing or concomitant bleeding disorders.\n5. Active infections.\n6. Significant cardiovascular disease (e.g., controlled hypertension, unstable angina, NYHA class ≥ II congestive heart failure, unstable symptomatic arrhythmias, or ≥ II peripheral vascular disease) or any condition deemed intolerable to chemotherapy by the oncology department.",{"count":376,"type":20},315,[52],"This study aims to evaluate the efficacy of adjuvant docetaxel chemotherapy following radical radiotherapy in patients with localized high-grade prostate cancer. Eligible participants include those diagnosed with prostate cancer confirmed by biopsy or surgical pathology, with a Gleason score of 9-10 or containing a Gleason 5 component, and no evidence of distant metastasis. Patients will be divided into two groups: the standard treatment group receiving only radical treatment (radiotherapy or surgery), and the standard treatment plus chemotherapy group, receiving four to six cycles of docetaxel chemotherapy after standard treatment. The primary endpoint is Failure-Free Survival (FFS), with secondary endpoints including Biochemical Relapse-Free Survival (BRFS), Metastasis-Free Survival (MFS), Overall Survival (OS), and assessment of adverse events The study aims to better understand the impact of adjuvant chemotherapy on the prognosis of patients with high-risk prostate cancer and determine whether it improves survival outcomes.",[380,27,381,382],"Prostate Cancer","Chemotherapy","Gleason Score","2025-04-20",{"date":385,"type":33},"2025-04-24",{"date":387,"type":33},"2019-09-01",{"date":389,"type":20},"2031-09-01",{"name":117,"class":40},{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":126,"minAge":17,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":21,"phases":400,"briefSummary":401,"conditions":402,"keywords":406,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":41},"100489064","feasibility-of-hyivy-device-post-radiation-for-pelvic-malignancies-100489064","NCT05648253","Feasibility of Hyivy Device Post-Radiation for Pelvic Malignancies","Pilot Study to Assess the Feasibility of Use of a Novel Vaginal Dilator Device Post-radiation for Patients With Pelvic Malignancies","Inclusion Criteria:\n\n* 1.Age ≥ 18 at the time of enrollment\n* 2.Patient with a vagina or vaginal canal who have completed radiation therapy (either external beam or brachytherapy, or a combination of both) for endometrial cancer, cervical cancer, anal cancer, or rectal cancer, without concomitant chemotherapy\n* 3.Generally in good health (other than due to cancer), at the discretion of the investigator(s)\n* 4.Eastern Cooperative Oncology Group (ECOG) score or 0 to 2\n* 5.Participants must be post-menopausal (natural or surgically) for at least 1 year prior to screening or be surgically sterile (absence of ovaries and\u002For uterus); or, a participant of child-bearing potential must agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months.\n* 6.Agree not to use other dilators for the 12-week intervention period\n* 7.Must have the ability to charge the investigational device\n* 8.Must be willing and able to insert intravaginal device\n* 9.Able to understand, comply and consent to protocol requirements and instructions\n* 10.Able to attend scheduled study visits and complete required investigations\n* 11.Ability to understand and willingness to sign written informed consent\n\nExclusion Criteria:\n\n* 1.Participants who are pregnant or planning to become pregnant during the trial\n* 2.Any major surgery in the past 3 months unless post-surgery dilator use is recommended by a physician, or anticipates having a major surgery during the study\n* 3.Any other medical condition or clinical finding giving reasonable suspicion of a disease or condition that contraindicates the use of the investigational product or that may affect the interpretation of the results or leave the patient at high risk from treatment complications, at the discretion of the investigator(s)\n* 4.Allergy to Hyivy device's materials\n* 5.Active pelvic or gynaecological infection\n* 6.Current use of antibiotics for any infection\n* 7.Have open wounds, cuts, or open sores present in the vaginal or pelvic area\n* 8.Severe atrophic vaginitis or very dry, itchy, or sore vagina\u002Fvaginal area, at the discretion of the investigator(s)\n* 9.Hypoesthesia or loss in sensation of the pelvic floor\n* 10.Total and\u002For partial prolapse of the uterus and\u002For vagina\n* 11.Symptoms of severe urinary retention, severe extra-urethral incontinence, or overflow incontinence\n* 12.Unable to position the device according to directions for use\n* 13.Use of any medical devices that may interfere with the investigational device's function, such as pacemakers, ventilators, and ear implants",{"count":399,"type":20},12,[52],"Vaginal dilator therapy (VDT) with static dilators is often prescribed to patients following vaginal or pelvic radiation therapy. This study seeks to evaluate the feasibility of a novel intravaginal device that delivers patient-controlled dilation (Hyivy device). The study is designed as a proof-of-concept single-arm pilot study. The primary objective is to assess safety and tolerability, while also evaluating changes in health-related quality of life and pelvic pain.",[403,27,83,404,405],"Vaginal Stenosis","Pelvic Pain","Pelvic Cancer",[407,408],"Dilator","Post radiation therapy","2025-04-17",{"date":411,"type":33},"2025-04-22",{"date":413,"type":33},"2025-04-11",{"date":415,"type":20},"2026-06",{"name":417,"class":418},"Hyivy Health Inc","INDUSTRY",{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":21,"phases":428,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":41},"100584462","phase-2-sabr-combined-with-axitinib-and-toripalimab-in-recurrent-or-metastatic-rcc-100584462","NCT06889649","SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC","Prospective Study on the Efficacy and Safety of Stereotactic Ablative Body Radiotherapy Combined with Axitinib and Toripalimab in Recurrent or Metastatic Renal Cell Carcinoma","Inclusion Criteria:\n\n1. Histopathologically confirmed renal cell carcinoma with recurrent metastatic lesions confirmed by PET\u002FCT or other systemic imaging.\n2. Patients with ≤5 metastatic lesions amenable to complete lesion coverage radiotherapy; or \\>5 lesions with at least 3 suitable for radiotherapy as evaluated by the radiotherapy and imaging departments.\n3. Age between 18-80 years.\n4. Expected survival of ≥12 weeks.\n5. Measurable disease based on RECIST Version 1.1.\n6. ECOG performance status of 0-2.\n\nExclusion Criteria:\n\n1. History of anti-PD-1 or PD-L1 antibody therapy, or radiotherapy.\n2. Use of corticosteroids or other immunosuppressants within 14 days before treatment.\n3. Autoimmune diseases.\n4. History of other malignancies.\n5. History of surgery within 28 days before treatment.\n6. Allergy to study drug components.","80 Years",{"count":19,"type":20},[206],"This is a prospective, single-center clinical trial designed to evaluate the safety and efficacy of combining stereotactic ablative body radiotherapy (SABR) with the targeted therapy Axitinib and the immunotherapy Toripalimab in patients with recurrent metastatic renal cell carcinoma (RCC). Patients will receive a treatment regimen consisting of Axitinib, Toripalimab, and comprehensive multi-lesion SABR. The primary endpoint is Progression-Free Survival 1 (PFS1), and secondary endpoints include Progression-Free Survival 2 (PFS2), Overall Survival (OS), Local Control (LC), Objective Response Rate (ORR), and Disease Control Rate (DCR). Adverse events will be monitored according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0). The aim of this study is to explore a potentially more effective treatment combination for recurrent metastatic RCC.",[27,431,432,433],"Targeted Therapy","Immunotherapy","Renal Cancer Metastatic","2025-03-19",{"date":436,"type":33},"2025-03-21",{"date":438,"type":33},"2019-01-01",{"date":440,"type":20},"2028-02-20",{"name":117,"class":40},{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":449,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":4},"100581742","clarity-study---pmcf-study-100581742","NCT06854263","CLARITY Study - PMCF Study","ProspeCtive, muLti-site, Single-group, Open-lAbel Study to Evaluate the Safety and Performance of RADSAFE® Inks for radiaTion therapY Site Marking (CLARITY Study)","Inclusion Criteria:\n\nMale or female ≥18 years old, Cancer patient requiring radiotherapy, Patient requiring medical tattoo for treatment alignment, Intact skin at site of standard radiotherapy tattoos, ECOG performance status ≤2 (Karnofsky ≥60%), Able to provide written informed consent, Affiliated patient or beneficiary of a social security scheme.\n\nExclusion Criteria:\n\nPrevious medical tattoo of the targeted zone of treatment Known allergy to pigment ingredients, Infected or diseased skin, past or present, Affected organs close to the skin (eyes), Hypertrophic scars at site of radiotherapy tattoos, Carrying cardiac implant, Patient with blood clotting disorders, No consent to study participation, Under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision, An existing medical condition that, in the opinion of the Investigator, may put the subject at risk or compromise their participation in the study, Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements, Females who are pregnant, lactating, or unwilling to use adequate birth control for the duration of the study, Personal objection to medical tattooing, Participation to another drug or medical device clinical interventional study that may interfere with the clinical investigation objectives.",{"count":450,"type":20},119,"In the context of the Post-Market Clinical Follow-up (PMCF), this study aimed at evaluating the safety and performance of the RADSAFE® inks in the marking of the radiation field.",[27],"2025-03-03",{"date":455,"type":33},"2025-03-05",{"date":457,"type":20},"2025-04",{"date":459,"type":20},"2025-12",{"name":461,"class":418},"Laboratoires BIOTIC Phocea",{"id":463,"slug":464,"hasResults":11,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":468,"eligibilityCriteria":469,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":426,"enrollmentInfo":470,"targetDuration":4,"studyType":21,"phases":472,"briefSummary":473,"conditions":474,"keywords":478,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":492,"leadSponsor":494,"locationsCount":41},"100580169","application-of-intelligent-care-systems-in-radiation-therapy-enhancing-patient-safety-and-reducing-anxiety-through-system-optimization-and-real-time-blood-data-monitoring-100580169","NCT06833801","Application of Intelligent Care Systems in Radiation Therapy: Enhancing Patient Safety and Reducing Anxiety Through System Optimization and Real-Time Blood Data Monitoring","Application of Intelligent Care Systems in Radiation Therapy: Enhancing Patient Safety and Reducing Anxiety Through System Optimization, Enhanced Education Strategies, and Real-Time Blood Data Monitoring","ICS-RT","Inclusion Criteria:\n\n* Patients undergoing radiation therapy combined with chemotherapy.\n* Age ≥ 18 years.\n* Ability to understand and comply with the study protocol.\n* Willing to participate in the study and provide informed consent.\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment or intellectual disability, affecting their ability to understand or follow study procedures.\n* Patients unwilling to complete study questionnaires.\n* Any mental health condition (e.g., major depressive disorder, severe anxiety disorder) that could interfere with participation.\n* Patients with conditions requiring immediate intervention that would make study participation impractical.",{"count":471,"type":20},100,[52],"This study aims to evaluate the impact of an intelligent care system on radiation therapy patients, focusing on real-time blood data monitoring, optimized patient education, and internal alert systems. The goal is to enhance patient safety, improve treatment adherence, and reduce anxiety by integrating an alert function into the hospital's existing system.\n\nKey interventions include:\n\nReal-time blood monitoring alerts: Healthcare providers will receive automatic notifications of abnormal blood test results to ensure timely intervention.\n\nOptimized patient education materials: Clearer guidance will help patients proactively communicate blood test needs and manage their health during radiation therapy.\n\nInternal reminders: Visual signs and alerts in treatment areas will reinforce patient awareness and engagement.\n\nThe study will compare patients receiving these interventions with those under standard care, assessing treatment compliance, anxiety levels, and clinical outcomes over a 12-month period.",[27,475,476,477],"Chemoradiotherapy","Anxiety","Adherence",[27,479,480,481,482,483,484,485,486,487],"Intelligent Care System","Real-Time Blood Data Monitoring","Patient Safety","Oncology Treatment Compliance","Cancer Treatment Anxiety","Clinical Decision Support System","Health Education in Radiation Oncology","Automated Blood Test Alerts","Supportive Care in Cancer Patients","2025-02-18",{"date":490,"type":33},"2025-02-20",{"date":490,"type":20},{"date":493,"type":20},"2025-12-31",{"name":495,"class":40},"Chung Shan Medical University",{"id":497,"slug":498,"hasResults":11,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":21,"phases":505,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":241},"100463617","increased-early-pain-relief-by-adding-vertebroplasty-to-sbrt-100463617","NCT05317026","Increased Early Pain Relief by Adding Vertebroplasty to SBRT","Pre-irradiation Vertebroplasty in Patients With Spine Metastases Candidates for SBRT vs SBRT Alone: Increased Early Pain Relief","Inclusion Criteria:\n\n* Histological evidence of cancer.\n* Spinal and vertebral bone metastases (T5 to L5) documented by imaging.\n* Pain related to metastases ≥ 4 on a numerical scale 0-10.\n* Karnofsky performance index \\> 60 (ecog 0-2)\n* Candidate for SBRT\n* Less than 3 consecutive levels reached.\n* Ability to complete follow-up questionnaires regarding pain, analgesics, and quality of life assessment.\n* Potentially unstable lesions according to the spinal instability neoplastic score (SINS) scale (\\> or = 7)\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Contraindications to MRI.\n* Histology: myeloma, lymphoma or plasmacytoma.\n* Radiotherapy prior to the level to be treated.\n* Previous surgery at the site to be treated.\n* Surgical indication:\n\nspinal instability neoplastic score (SINS) \\> 13 or according to tumor board consensus.\n\nBilsky score \\> or = 2 Severe or progressive neurological signs (motor, incontinence).\n\n* Lesion too large for safe vertebroplasty.\n* High thoracic location not allowing safe visibility in fluoroscopy to perform vertebroplasty (T4 and above).\n* Non-reversible coagulation disorders.\n* Uncontrolled local or systemic infection.\n* Estimated survival of less than 6 months.\n* Inability or refusal to undergo SBRT treatment or vertebroplasty",{"count":504,"type":20},50,[52],"The goal of treating metastases is to preserve stability and neurological function while reducing pain. The actual standard of care is stereotaxic body radiation therapy (SBRT) alone in non-surgical patients. The added value of vertebroplasty to SBRT is not well documented in the literature, nor whether performing vertebroplasty before radiotherapy treatment leads to a reduction in the rate of fractures and post-SBRT pain.",[508,27,357],"Spine Metastases","2024-08-06",{"date":511,"type":33},"2024-08-07",{"date":513,"type":33},"2023-11-22",{"date":515,"type":20},"2027-12-31",{"name":517,"class":40},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":519,"slug":520,"hasResults":11,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":527,"conditions":528,"keywords":532,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":41},"100341864","prospective-observational-trial-to-evaluate-quality-of-life-after-neoadjuvant-radiation-or-chemoradiation-followed-by-surgery-in-patients-with-rectal-cancer-100341864","NCT03731130","Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer","Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer","NEOCARE","Inclusion Criteria:\n\n* histologically proven rectal Cancer without distant metastases\n* indication for neoadjuvant Radiation or chemoradiation therapy according to multidiciplinary Evaluation\n* age \\>=18 years\n* written informed consent\n* ability to answer the standardized questionaires according to the treating physician\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* prior systemic therapy with regard to rectal Cancer\n* distant metastasis\n* second malignancy",{"count":471,"type":20},"Observational study to evaluate longitudinal quality of life according to standardized EORTC questionaires as well as functional Outcome, oncological outcome and toxicity in patients treated with neoadjuvant short term radiation or long-term chemoradiation followed by surgery",[529,530,27,531],"Rectal Cancer","Quality of Life","Chemoradiation",[533,534,535,56,536],"rectal cancer","quality of life","neoadjuvant","chemoradiation","2018-11-02",{"date":539,"type":33},"2018-11-06",{"date":541,"type":33},"2018-10-05",{"date":543,"type":20},"2026-12-31",{"name":545,"class":40},"Ludwig-Maximilians - University of Munich"]